Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Minocycline treatment for rheumatoid arthritis: an open dose finding study.
How Natalizumab Binds and Antagonizes α4 Integrins.
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.
Food and Drug Administration briefing document for ofatumumab
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
High dose thiamine improves fatigue in multiple sclerosis.
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
FDA approves Ampyra to improve walking in adults with multiple sclerosis
Absence of mannose-binding lectin in a female with relapsing-remitting multiple sclerosis.
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.
Improving Hand Functional Use in Subjects with Multiple Sclerosis Using a Musical Keyboard: A Randomized Controlled Trial.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
Frequency of obsessive-compulsive disorder in patients with multiple sclerosis: A cross-sectional study.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Self-perceived performance and satisfaction with performance of daily activities in persons with multiple sclerosis following interdisciplinary rehabilitation.
Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Managing fatigue in patients with multiple sclerosis.
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
Cancer risk in multiple sclerosis: findings from British Columbia, Canada.

Pages